Breaking Finance News

Atara Biotherapeutics Inc (NASDAQ:ATRA) has been upgraded to Hold in a statement by Zacks Investment Research today.

Yesterday Atara Biotherapeutics Inc (NASDAQ:ATRA) traded 0.63% higher at $19.18. Atara Biotherapeutics Inc’s 50-day average is $21.76 and its two hundred day average is $19.94. The last close is down 3.20% from the 200-day average, compared with the Standard & Poor’s 500 Index which has fallen -0.01% over the same period. Volume of trade was was up over the average, with 279,612 shares of ATRA changing hands over the typical 212,820 shares..

Zacks Investment Research has upgraded Atara Biotherapeutics Inc(NASDAQ:ATRA) to Hold in a statement released 9/16/2016.

On 9/15/2016, Goldman Sachs Group Inc. released a statement for Atara Biotherapeutics Inc(NASDAQ:ATRA) dropped the target price from $23.00 to $16.00. At the time, this suggested a downside of -0.25%.

Recent Performance Graph:

Atara Biotherapeutics Inc (NASDAQ:ATRA)

Also covering Atara Biotherapeutics Inc’s price target, a total of 5 equity analysts have released a ratings update on Atara Biotherapeutics Inc. The consensus target stock price is $28.60 with three firms rating the company a strong buy, one analyst rating the company a buy, one analyst rating the stock a hold, 0 rating the stock to underperform, and lastly one brokerage rating the stock as sell.

Atara Biotherapeutics Inc has a 52 week low of $13.31 and a 52 week high of $49.48 and has a total market value of $0.0.

General Company Details For Atara Biotherapeutics Inc (NASDAQ:ATRA)

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics. Its T-cell product candidates include Epstein Barr Virus-cytotoxic T lymphocytes (EBV-CTL), which is in Phase II clinical trials for malignancies associated with EBV; cytomegalovirus (CMV)-CTL, which is in Phase II clinical trials for CMV, and Wilms Tumor 1 (WT1)-CTL, which targets cancers expressing the antigen WT1. Its molecularly targeted product candidates include STM 434, which is in Phase I clinical trial of STM 434 for ovarian cancer and other solid tumors; ATA 777, a fully human antibody targeting Activin A; ATA M43, a fully human anti-Actin-related protein 2-A (ActR2A)/2B monoclonal antibody; STM 217; ActR2B5, and ATA 842, and a humanized antibody targeting myostatin.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.